The Concept of CMR
Slides, videos and moreEvaluating CMR
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
NCEP-ATP III
- 1Key Points (1 page)
- 2The NCEP-ATP III Statement of 2001 (2 pages)
- 3Etiology and Treatment of the Metabolic Syndrome and its Components According to NCEP-ATP III (4 pages)
- 4NCEP-ATP III Clinical Tools for Diagnosing the Metabolic Syndrome and Type 2 Diabetes/CVD Risk (3 pages)
- 5References (1 page)
NCEP-ATP III Clinical Tools for Diagnosing the Metabolic Syndrome and Type 2 Diabetes/CVD Risk
9 of 11
Figure: 
Figure: The Hoorn Study is another population-based cohort study that evaluated incidence of fatal and non-fatal CVD in 1,364 men and women 50 to 75 years of age with and without metabolic syndrome over a 10 year follow-up (16). In men, the hazard ratio for fatal and non-fatal CVD was 1.91 (95% CI, 1.31-2.79), and the hazard ratio for fatal and non-fatal CVD in women was 1.68 (95% CI, 1.11-2.55). The metabolic syndrome clinical criteria of the World Health Organization, European Group for the Study of Insulin Resistance, and American College of Endocrinology were also evaluated. Results are presented in Comparison of Screening Tools.
The findings of two meta-analyses that used NCEP-ATP III clinical criteria to evaluate the association between metabolic syndrome and CVD were published recently. Galassi et al. (17) examined a total of 21 prospective studies, 15 of which used NCEP-ATP III clinical criteria for diagnosing the metabolic syndrome. In these 15 studies, compared to individuals without the metabolic syndrome, individuals with the metabolic syndrome had a relative CVD risk of 1.61 (95% CI, 1.42-1.83). The authors also found that the metabolic syndrome was positively and significantly associated with all-cause mortality, CVD mortality, CVD incidence, CHD incidence, and stroke incidence. Subgroup analyses also suggested that the association between the metabolic syndrome and incident CVD was stronger in women than in men. The Figure provides an overview of some of the studies that were considered in the meta-analysis using NCEP-ATP III clinical criteria. The other meta-analysis of 22 studies was performed by Gami et al. (18). This study used NCEP-ATP III clinical criteria (or modified NCEP-ATP III criteria). The RR for cardiovascular events was 1.67 when NCEP-ATP III criteria were available. In accordance with the other meta-analysis, this association was found to be stronger in women than in men. Interestingly, the meta-analysis by Gami et al.(18) suggested that the metabolic syndrome better predicted cardiovascular risk than the sum of its individual components.
9 of 11
